Exploring uncharted territories in immunomodulation
Butyrophilins & Gamma-delta T cells
ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.
For a second year, ImCheck has been selected by the French Tech as one of the top 120 French startups and of the 9 biotech companies developing innovative therapies
Leadership & CorporateRead more
ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01
Science & MedicineRead more